Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14471709 | 1.00 | CASR (0.79) | CASRLTA4H | |
| SCHEMBL14642109 | 0.91 | CASR (0.79) | CASRLTA4H | |
| SCHEMBL14617497 | 0.88 | CASR (0.76) | CASRLTA4H | |
| SCHEMBL14791484 | 0.88 | CASR (1.00) | CASRLTA4H | |
| SCHEMBL14617496 | 0.86 | CASR (0.73) | CASR | |
| SCHEMBL14791481 | 0.85 | CASR (1.00) | CASR | |
| SCHEMBL14791511 | 0.85 | CASR (0.78) | CASR | |
| SCHEMBL14617500 | 0.85 | CASR (0.72) | CASRLTA4H | |
| SCHEMBL14471824 | 0.85 | CASR (0.72) | CASR | |
| SCHEMBL17682894 | 0.85 | CASR (0.77) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103951615-B | Alkylamine derivative | EA制药株式会社 | 2017-04-12 | — | — | CN | disclosed |
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012054530-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281394-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CASR 150/4885LTA4H 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.